The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials

The devastating Ebola virus (EBOV) epidemic in West Africa in 2013–2016 accelerated the progress of several vaccines and antivirals through clinical trials, including the replication-competent vesicular stomatitis virus-based vaccine expressing the EBOV glycoprotein (VSV-EBOV). Extensive preclinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Suder, Ellen, Furuyama, Wakako, Feldmann, Heinz, Marzi, Andrea, de Wit, Emmie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6183239/
https://www.ncbi.nlm.nih.gov/pubmed/29757706
http://dx.doi.org/10.1080/21645515.2018.1473698
_version_ 1783362694680674304
author Suder, Ellen
Furuyama, Wakako
Feldmann, Heinz
Marzi, Andrea
de Wit, Emmie
author_facet Suder, Ellen
Furuyama, Wakako
Feldmann, Heinz
Marzi, Andrea
de Wit, Emmie
author_sort Suder, Ellen
collection PubMed
description The devastating Ebola virus (EBOV) epidemic in West Africa in 2013–2016 accelerated the progress of several vaccines and antivirals through clinical trials, including the replication-competent vesicular stomatitis virus-based vaccine expressing the EBOV glycoprotein (VSV-EBOV). Extensive preclinical testing in animal models demonstrated the prophylactic and post-exposure efficacy of this vaccine, identified the mechanism of protection, and suggested it was safe for human use. Based on these data, VSV-EBOV was extensively tested in phase 1–3 clinical trials in North America, Europe and Africa. Although some side effects of vaccination were observed, these clinical trials showed that the VSV-EBOV was safe and immunogenic in humans. Moreover, the data supported the use of VSV-EBOV as an emergency vaccine in individuals at risk for Ebola virus disease. In this review, we summarize the results of the extensive preclinical and clinical testing of the VSV-EBOV vaccine.
format Online
Article
Text
id pubmed-6183239
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-61832392018-10-19 The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials Suder, Ellen Furuyama, Wakako Feldmann, Heinz Marzi, Andrea de Wit, Emmie Hum Vaccin Immunother Review The devastating Ebola virus (EBOV) epidemic in West Africa in 2013–2016 accelerated the progress of several vaccines and antivirals through clinical trials, including the replication-competent vesicular stomatitis virus-based vaccine expressing the EBOV glycoprotein (VSV-EBOV). Extensive preclinical testing in animal models demonstrated the prophylactic and post-exposure efficacy of this vaccine, identified the mechanism of protection, and suggested it was safe for human use. Based on these data, VSV-EBOV was extensively tested in phase 1–3 clinical trials in North America, Europe and Africa. Although some side effects of vaccination were observed, these clinical trials showed that the VSV-EBOV was safe and immunogenic in humans. Moreover, the data supported the use of VSV-EBOV as an emergency vaccine in individuals at risk for Ebola virus disease. In this review, we summarize the results of the extensive preclinical and clinical testing of the VSV-EBOV vaccine. Taylor & Francis 2018-06-18 /pmc/articles/PMC6183239/ /pubmed/29757706 http://dx.doi.org/10.1080/21645515.2018.1473698 Text en This article not subject to US copyright law. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Review
Suder, Ellen
Furuyama, Wakako
Feldmann, Heinz
Marzi, Andrea
de Wit, Emmie
The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials
title The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials
title_full The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials
title_fullStr The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials
title_full_unstemmed The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials
title_short The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials
title_sort vesicular stomatitis virus-based ebola virus vaccine: from concept to clinical trials
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6183239/
https://www.ncbi.nlm.nih.gov/pubmed/29757706
http://dx.doi.org/10.1080/21645515.2018.1473698
work_keys_str_mv AT suderellen thevesicularstomatitisvirusbasedebolavirusvaccinefromconcepttoclinicaltrials
AT furuyamawakako thevesicularstomatitisvirusbasedebolavirusvaccinefromconcepttoclinicaltrials
AT feldmannheinz thevesicularstomatitisvirusbasedebolavirusvaccinefromconcepttoclinicaltrials
AT marziandrea thevesicularstomatitisvirusbasedebolavirusvaccinefromconcepttoclinicaltrials
AT dewitemmie thevesicularstomatitisvirusbasedebolavirusvaccinefromconcepttoclinicaltrials
AT suderellen vesicularstomatitisvirusbasedebolavirusvaccinefromconcepttoclinicaltrials
AT furuyamawakako vesicularstomatitisvirusbasedebolavirusvaccinefromconcepttoclinicaltrials
AT feldmannheinz vesicularstomatitisvirusbasedebolavirusvaccinefromconcepttoclinicaltrials
AT marziandrea vesicularstomatitisvirusbasedebolavirusvaccinefromconcepttoclinicaltrials
AT dewitemmie vesicularstomatitisvirusbasedebolavirusvaccinefromconcepttoclinicaltrials

Ejemplares similares